EP1064022A4 - HLA BINDING PEPTIDES AND THEIR APPLICATIONS - Google Patents

HLA BINDING PEPTIDES AND THEIR APPLICATIONS

Info

Publication number
EP1064022A4
EP1064022A4 EP98910404A EP98910404A EP1064022A4 EP 1064022 A4 EP1064022 A4 EP 1064022A4 EP 98910404 A EP98910404 A EP 98910404A EP 98910404 A EP98910404 A EP 98910404A EP 1064022 A4 EP1064022 A4 EP 1064022A4
Authority
EP
European Patent Office
Prior art keywords
applications
binding peptides
hla binding
hla
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98910404A
Other languages
German (de)
French (fr)
Other versions
EP1064022A1 (en
Inventor
Alessandro Sette
Ralph T Kubo
John Sidney
Esteban Celis
Howard M Grey
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1064022A1 publication Critical patent/EP1064022A1/en
Publication of EP1064022A4 publication Critical patent/EP1064022A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP98910404A 1998-03-13 1998-03-13 HLA BINDING PEPTIDES AND THEIR APPLICATIONS Withdrawn EP1064022A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/005039 WO1999045954A1 (en) 1998-03-13 1998-03-13 Hla-binding peptides and their uses

Publications (2)

Publication Number Publication Date
EP1064022A1 EP1064022A1 (en) 2001-01-03
EP1064022A4 true EP1064022A4 (en) 2004-09-29

Family

ID=22266589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98910404A Withdrawn EP1064022A4 (en) 1998-03-13 1998-03-13 HLA BINDING PEPTIDES AND THEIR APPLICATIONS

Country Status (5)

Country Link
EP (1) EP1064022A4 (en)
JP (1) JP2002507397A (en)
AU (1) AU6465598A (en)
CA (1) CA2323632A1 (en)
WO (1) WO1999045954A1 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
WO2000020445A2 (en) * 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
CN1334873A (en) * 1998-12-01 2002-02-06 伊东恭悟 Tumor Antigen protein ART-1 and tumor antigen peptide thereof
IT1309584B1 (en) * 1999-02-26 2002-01-24 San Raffaele Centro Fond IMMUNOGENIC PEPTIDES DERIVED FROM MAGE-3 PRESENTED BY MHC OF CLASS II AND THEIR USE.
WO2001032193A1 (en) * 1999-10-29 2001-05-10 Argonex Pharmaceuticals Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
EP1230268B1 (en) * 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
CA2393662A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
JP2003517310A (en) * 1999-12-10 2003-05-27 エピミューン， インコーポレイテッド Induction of a cellular immune response against MAGE2 / 3 using peptide and nucleic acid compositions
EP1239866A4 (en) * 1999-12-10 2005-02-09 Epimmune Inc INDUCTION OF CELLULAR IMMUNE RESPONSE TO HER2 / NEW WITH THE HELP OF PEPTIDE AND NEW SMARTIC ACID PREPARATIONS
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
JP2003521245A (en) * 1999-12-21 2003-07-15 エピミューン， インコーポレイテッド Inducing a Cellular Immune Response to Prostate Cancer Antigen Using Peptide and Nucleic Acid Compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
FR2806727A1 (en) * 2000-03-23 2001-09-28 Pf Medicament MOLECULE OF PHARMACEUTICAL INTEREST COMPRISING IN THE N-TERMINAL END A GLUTAMIC ACID OR GLUTAMINE IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALT
WO2001074847A2 (en) * 2000-03-30 2001-10-11 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
CN1107681C (en) * 2000-08-11 2003-05-07 中国科学院微生物研究所 Compound of polypeptide as antigen of hepatitis B virus and heat shock protein and its application
EP1366153A2 (en) * 2000-08-14 2003-12-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies
CA2421448A1 (en) * 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
EP1195381A1 (en) * 2000-09-28 2002-04-10 Immusystems GmbH Hepatitis c virus epitopes specific for cd4+ t-cell lymphocytes
US7241742B2 (en) 2000-10-31 2007-07-10 Mgi Pharma Biologics, Inc. CYP1B1 nucleic acids and methods of use
EP1490396A4 (en) * 2001-03-01 2006-04-19 Us Gov Health & Human Serv IMMUNOGENEOUS HIV PEPTIDES FOR USE AS REAGENTS AND VACCINES
US7252824B2 (en) * 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
EP1752160A3 (en) * 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2002305138A1 (en) 2001-04-09 2002-10-21 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US7842480B2 (en) 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7223836B2 (en) 2001-06-05 2007-05-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Peptides for chlamydophila pneumoniae vaccine and diagnosis
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
CA2357906A1 (en) * 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
CN101024842A (en) 2001-11-07 2007-08-29 曼康公司 Expression vectors encoding epitopes of target-associated antigens and its design method
AU2002349543A1 (en) * 2001-12-10 2003-06-23 Kyogo Itoh Tumor antigens
EP1495322A4 (en) * 2002-04-05 2006-09-06 Epimmune Inc HETEROCLITITIC ANALOGUES AND ASSOCIATED METHODS
EP2336189A1 (en) 2003-01-28 2011-06-22 Proscan RX Pharma Prostate cancer diagnosis and treatment
WO2005007694A1 (en) * 2003-07-16 2005-01-27 Green Peptide Co., Ltd. HER2/neu PEPTIDE AND THERAPEUTIC USE TEHREOF
CA2537900A1 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
CN1856503A (en) * 2003-09-22 2006-11-01 株式会社绿多肽 Peptides derived from hepatitis C virus
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
WO2005103679A2 (en) 2004-04-21 2005-11-03 Algonomics Nv Method for affinity scoring of peptide/protein complexes
US20080249283A1 (en) * 2004-04-30 2008-10-09 Tomoya Miyakawa Hla-Binding Peptides, Precursors Thereof, Dna Fragments and Recombinant Vectors that Code for Those Peptide Sequences
JP5176099B2 (en) * 2004-09-27 2013-04-03 国立大学法人 東京医科歯科大学 HLA-A11 restricted Tax anti-tumor epitope
US20080306243A1 (en) * 2005-09-07 2008-12-11 Nec Corporation Hla-Binding Peptide, and Dna Fragment and Recombinant Vector Coding for Said Hla-Binding Peptide
US8378072B2 (en) 2006-04-13 2013-02-19 Declion Pharmaceuticals, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
AP3467A (en) 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
US8728492B2 (en) 2008-01-18 2014-05-20 Aeras Global Tb Vaccine Foundation Malaria vaccine compositions and constituents which elicit cell mediated immunity
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
US9265822B2 (en) * 2009-09-30 2016-02-23 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
JP5930967B2 (en) * 2010-09-08 2016-06-08 学校法人 埼玉医科大学 Hepatitis C virus liposome vaccine
CN103561771B (en) 2011-03-17 2019-01-04 伯明翰大学 redirected immunotherapy
CN102286075A (en) * 2011-08-01 2011-12-21 中国人民解放军第三军医大学 Hepatitis B virus surface antigen immunodominance HLA-A*1101 restricted cytotoxic T lymphocyte (CTL) epitope and use thereof
US9517252B2 (en) 2011-09-09 2016-12-13 Agency For Science, Technology And Research p53 activating peptides
AU2013210783B2 (en) * 2012-01-20 2017-12-07 Cellvax Therapeutics Inc. Autologous cancer cell vaccine
JP5999703B2 (en) * 2013-01-09 2016-09-28 国立大学法人 東京医科歯科大学 HLA-DR1-restricted Tax-specific CD4 + T cell epitope
ES2727552T3 (en) * 2015-02-18 2019-10-17 Hoffmann La Roche Immunoconjugates for the specific induction of cytotoxicity of T lymphocytes against a target cell
CN105037559B (en) * 2015-08-17 2018-09-25 北京康爱瑞浩生物科技股份有限公司 Treat or prevent the cytotoxic T lymphocyte and preparation method thereof of hepatitis B
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI782434B (en) 2015-08-28 2022-11-01 德商英麥提克生物技術股份有限公司 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
KR20190129032A (en) 2016-12-28 2019-11-19 인벡스, 인크. Influenza vaccine
JP7385556B2 (en) * 2017-09-01 2023-11-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Immunogenic peptides specific for BCMA antigens and uses thereof
EP3545967A1 (en) * 2018-03-28 2019-10-02 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer immunization platform
US12247053B2 (en) 2018-10-26 2025-03-11 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
CN113939527B (en) * 2019-01-11 2025-10-28 新加坡科技研究局 Use of HLA-A*11:01-restricted hepatitis B virus (HBV) peptides for identifying HBV-specific CD8+ T cells
KR20210144737A (en) 2019-03-04 2021-11-30 유니버시티 헬스 네트워크 T cell receptors and methods of use thereof
US20220168346A1 (en) * 2019-03-04 2022-06-02 University Health Network T cell receptors and methods of use thereof
CN113795584B (en) 2019-03-04 2025-09-30 大学健康网络 T cell receptors and methods of use thereof
EP3935175A4 (en) 2019-03-04 2023-01-04 University Health Network T cell receptors and methods of use thereof
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
MX2021011462A (en) 2019-03-25 2021-12-15 Univ Health Network RECEPTORS OF T LYMPHOCYTES AND METHODS OF USE THEREOF.
CN115974986A (en) * 2019-12-13 2023-04-18 南京大户生物科技有限公司 Thymus-dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and its application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
WO1998032456A1 (en) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
WO1997033602A1 (en) * 1996-03-11 1997-09-18 Cytel Corporation Peptides with increased binding affinity for hla molecules
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
WO1998032456A1 (en) * 1997-01-23 1998-07-30 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALTUVIA YAEL ET AL: "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets", HUMAN IMMUNOLOGY, vol. 58, no. 1, November 1997 (1997-11-01), pages 1 - 11, XP002279422, ISSN: 0198-8859 *
GREY H M ET AL: "CLASS I MHC-PEPTIDE INTERACTIONS: STRUCTURAL REQUIREMENTS AND FUNCTIONAL IMPLICATIONS", CANCER SURVEYS, OXFORD, GB, vol. 22, 1995, pages 37 - 49, XP008024840 *
PARTIDOS C D ET AL: "Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides", IMMUNOLOGY, vol. 87, no. 2, 1996, pages 179 - 185, XP002279421, ISSN: 0019-2805 *
See also references of WO9945954A1 *

Also Published As

Publication number Publication date
EP1064022A1 (en) 2001-01-03
WO1999045954A1 (en) 1999-09-16
AU6465598A (en) 1999-09-27
CA2323632A1 (en) 1999-09-16
JP2002507397A (en) 2002-03-12

Similar Documents

Publication Publication Date Title
EP1064022A4 (en) HLA BINDING PEPTIDES AND THEIR APPLICATIONS
ATA1198A (en) SNOWBOARD - ENTRY BINDING
EE05538B1 (en) Interleukin-18 binding proteins, their preparation and use
DE69827307D1 (en) turbocharger
DE69808854D1 (en) Bookbinding device
EP0888120A4 (en) HLA BINDING PEPTIDES AND USES
DE69828963D1 (en) WIRSTOFFABGE AND GENTHERAPY SYSTEM
DE69611955D1 (en) Binding element
DE59809278D1 (en) hysteresis
ATA144897A (en) SPINE PROSTHESIS
NO20002387D0 (en) Application wrapping procedures and systems
EP1263775A4 (en) HLA BINDING PEPTIDES AND USES THEREOF
EP0879283A4 (en) GLUTENIN GENES AND USES THEREOF
DE69716696D1 (en) MULTIPLE FOLDER AND MULTI-FOLDER
DK0865832T3 (en) sorting System
DE69817679D1 (en) particulate
DE69706521D1 (en) MODIFIED INULIN
DE69713417D1 (en) Transverse spine connector
DE69610791D1 (en) Binding device
TR199701666A3 (en) Proteins
KR960010685A (en) Peptides and their uses
DE69827522D1 (en) BINDING DEVICE
DE69811185D1 (en) folder
DE69506405D1 (en) BINDING DEVICE
FR2720748B1 (en) BTF2 complex proteins and their applications.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EPIMMUNE INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/82 B

Ipc: 7C 07K 14/02 B

Ipc: 7C 07K 7/00 B

Ipc: 7A 61K 39/00 B

Ipc: 7A 61K 39/29 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040813

17Q First examination report despatched

Effective date: 20070820

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080401